ClinicalTrials.gg
RecruitingNCT07362056Updated Jan 23, 2026

Implementing Suicide Prevention Into Primary Care in Nepal

An interventional study of Suicide Prevention Package (PSuPP) in Suicide and Primary Care, sponsored by Yale University. Recruiting at 1 site in Nepal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Primary conditionSuicide PreventionRegistry: SuicideReclassifiedWhy we changed it
Registry
Suicide — the first condition term the registry derived for this study.
ClinicalTrials.gg
Suicide Prevention
Why
  1. Suicide is a broad heading, used only when no more specific condition is named.
  2. The study's title name Suicide Prevention, a narrower term within Suicide.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Yale University · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Suicide remains a major contributor to global mortality, with particularly high and persistent rates in low-resourced settings such as South Asia. In Nepal, ongoing integration of mental health services into primary care provides a critical opportunity to strengthen suicide risk assessment and management. Despite the scale-up of mhGAP training for primary care providers (PCPs), gaps remain in the systematic detection, referral, and follow-up of individuals at risk for suicide. There is an urgent need to enhance mhGAP implementation with strategies that address provider workload, stigma, and inequities within the health workforce.

Using experience-based co-design principles and RE-AIM this study will assess the feasibility and acceptability of integrating an implementation strategy package to optimize mhGAP suicide prevention delivery in Nepal's decentralized primary healthcare system. This clinical trial leverages deep collaboration with a community advisory board of individuals with lived experience of suicide throughout the trials' design, delivery and analysis.

This R34 will generate critical preliminary evidence on the feasibility, acceptability, and implementation of an integrated suicide prevention package within government primary care facilities in Nepal. The findings will inform the design and parameters of a future fully powered effectiveness trial, while aligning with Nepal's national suicide prevention strategy and advancing WHO and NIMH global mental health priorities.

02

Conditions studied

  • Suicide
  • Primary Care

Browse trials for

Keywords

  • suicide prevention
  • primary care
  • implementation science
  • Nepal
03

In context

Suicide Prevention Reclassified

186 studies on the registry are indexed under Suicide Prevention; 92 are open to participants now.

This study's planned enrollment of 147 is close to the median of 140 across 167 interventional studies indexed under Suicide Prevention.

Browse Suicide Prevention studies →

Lead sponsor

Yale University is the lead sponsor of 1,770 studies on the registry; 294 are open to participants now.

Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.

Compared within Suicide Prevention, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Suicide. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Primary Care Providers

  • Health workers with a prescribing license employed in government health facilities in Bagmati Province.
  • Are between 21-65 years, per government health system criteria.
  • Participants will be required to have competency in Nepali, be actively engaged in care provision within their health facility

Patients:

  • Patient lives in the study site
  • Is under the care of a PCP at a facility site.
  • Patient meets any level of suicide risk based on mhGAP 2.0 criteria.
  • Patients who have been treated for mental illness before or presently (expected in both groups).
  • Speaks Nepali.
  • Levels of Suicide Risk (as defined by mhGAP 2.0)

Exclusion criteria

Exclusion Criteria:

Primary Care Providers

  • Healthcare workers without proper government credentials will be excluded.
  • Health workers who plan to migrate or who do not intend to stay in the study area for at least a year.

Patients:

  • Patient requiring immediate hospitalization
  • Unable to consent as determined by the diminished capacity tool.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
147 participants (estimated)

Study arms

  • No intervention
    Treatment As Usual

    PCPs will receive standard or refresher mhGAP training. The training follows Nepal's district mental health plan for primary care workers with prescribing credentials. Paramedical staff are included because most primary healthcare facilities lack doctors, making them the primary frontline primary care providers. The training is based on the WHO mhGAP Intervention Guide and focuses on five priority conditions in Nepal: depression, psychosis, epilepsy, alcohol use disorder, and suicide. Training is delivered over 5 days by a Nepali psychiatrist with government issued credentials to facilitate mhGap training and subsequent ongoing supervision. After training, PCPs receive psychiatric supervision approximately every three months as per the Nepal government mhGap protocol. Patient participants in the TAU arm will receive the services based on mhGAP treatment protocols.

  • Experimental
    TAU+Suicide Prevention Package (PSuPP)

    PCPs will receive all components of TAU. In addition, they receive an implementation package to optimize mhGAP siucide prevention delivery. The implementation package includes: \[assessment optimization\] systematic assessment training using systematized screening questions, an embedded decision-support tool, \[risk management optimization\] culturally adapted safety planning, and \[follow up care optimization\] a collaborative care protocol with Community Health Workers (CHWs) to support patient follow-up uptake and continued care. Participants in the PSuPP arm will receive all TAU services with aforementioned implementation strategies.

    Behavioral: Suicide Prevention Package (PSuPP)

Interventions

  • BehavioralSuicide Prevention Package (PSuPP)

    Implementation package to optimize mhGAP siucide prevention delivery which includes: \[assessment optimization\] systematic assessment training using systematized screening questions, an embedded decision-support tool, \[risk management optimization\] culturally adapted safety planning, and \[follow up care optimization\] a collaborative care protocol with CHWs to support patient follow-up uptake and continued care.

06

What researchers measure

Primary outcomes

  1. Percent intervention arm uptake to assess feasibility

    Percent primary care providers (PCPs) that attend the implementation training. Feasibility will be defined as 70% or more uptake.

    Time frame: 6 months

  2. Percentage of interviews that hold themes

    Qualitative feasibility acceptability data will be deemed acceptable if it demonstrates provider and patient perceptions of P-SuPP benefits to clinical care and mhGAP implementation and the absence of themes that suggest -SuPP is disruptive, unlikeable, and unacceptable. Acceptability will be assessed as the percentage of interviews that hold themes suggesting SuPP is disruptive, unlikeable, and unacceptable.

    Time frame: 6 months

  3. Percent retention to assess feasibility

    Percent participants enrolled (PCPs and Patients) who complete the study of all enrolled. Feasibility is established as retention of at least 65% completion of 6 month follow up of patients and PCPs.

    Time frame: 6 months

  4. Structured checklist to assess fidelity

    18-item structured checklist assessed in a standardized behavioral rehearsal to assess fidelity to the mhGAP suicide module protocol

    Time frame: 6 months

  5. Percent successful allocation procedures

    Percent successful allocation procedures followed

    Time frame: 6 months

  6. Percent adherence to the randomization protocol

    Percent adherence to the randomization protocol

    Time frame: 6 months

  7. Percent deviations to the randomization protocol

    Percent deviations to the randomization protocol

    Time frame: 6 months

  8. Percent participants who completed all follow up measures

    Percent participants who completed all follow up measures

    Time frame: 6 months

  9. Percent missing measure items per participant

    Percent missing measure items per participant

    Time frame: 6 months

  10. Mean Beck Scale for Suicide Ideation (BSSI) score

    Suicide ideation severity measured with BSSI. BSSI is a 19-item self-report instrument for detecting and measuring the current intensity of the patients' specific attitudes, behaviors, and plans to commit suicide during the past week. The first 19 items consist of three options graded are on a 3-point scale ranging from 0 to 2. These items are then summed to yield a total score, which ranges from 0 to 36. Higher scores indicate higher severity of suicide ideation. Assessed in patients only.

    Time frame: Baseline; 3 months; 6 months

Secondary outcomes

  1. Suicide Prevention Knowledge survey

    The mhGAP knowledge survey includes 9 items related to suicide specific knowledge related to suicide risk presentation, management, and carer engagement aligned with the mhGAP suicide prevention protocol. Total score range XXXXX. Higher scores indicate more knowledge. Assessed in PCPs only.

    Time frame: Baseline, 3 months; 6 months

  2. Mean Self-Efficacy in Mental Health Care survey score

    The mhGAP Self Efficacy is a self-administered measure assessing healthcare providers' confidence in assessing, diagnosing, and managing mental health conditions. Our adapted tool has 45 items across all domains and 8 items that focus specifically on suicide. Respondents select a range of responses between 1 and 5 with 1 feeling totally unable to do the domain and 5 feeling totally able to do the domain. Higher scores indicate higher self-efficacy. Assessed in PCPs only.

    Time frame: Baseline; 3 month; 6 month

  3. Mean Clinical Competency and Communication Skills (ENACT) score

    This is an observed role play with a trained rater to assess competence and interpersonal skills in delivering mental health interventions. The tool evaluates core competencies in psychological care delivery including: Communication, Emotional Engagement, Assessment, Social Relations, Planning and Process. communication skills, empathy, active listening, and patient engagement. Total score range 0-3. Higher scores indicate higher competence. Assessed in PCPs only.

    Time frame: Baseline; 6 months

  4. Columbia Suicide Severity Rating Scale

    The CSSRS asks about self-reported suicide attempt, aborted attempt, preparatory behavior, and interrupted attempt with "yes" or "no" questions branching format. Any positive responses to these behaviors will be coded as 'yes'. Behaviors are assessed at baseline as the past 3 months and lifetime and subsequent assessments have a window of the past three months. Participants will be categorized as low, medium or high risk based on their answers to specific questions. Assessed in patients only.

    Time frame: Baseline; 3 months; 6 months

  5. Mean Patient Health Questionnaire (PHQ-9) score

    Depression measured with PHQ-9. PHQ-9 is a 9-item validated questionnaire. Each item asks about the frequency of specific depressive symptoms experienced over the past two weeks. The response options are scored from 0 to 3, indicating "not at all" to "nearly every day." The item scores are summed with total score on the PHQ-9 ranges from 0 to 27, with higher scores indicating greater severity of depressive symptoms.

    Time frame: Baseline; 3 months; 6 months

  6. Mean Suicide Cognitions Scale (SCS) score

    The SCS includes 21 items that assess suicide-related cognitions, including negative expectations about the future, maladaptive self-perceptions, and emotional pain. The scale asks respondents to rate the extent to which they agree with experience specific suicide-related thoughts and beliefs. Responses are recorded on a Likert-type scale ranging from 1 to 5 from strongly disagree to strongly agree, and item scores are summed to produce a total score (21-105), with higher scores indicating greater severity of suicide-related cognitive distress. Assessed in patients only.

    Time frame: Baseline; 3 months; 6 months

  7. Suicide-Related Coping Scale (SRCS) - Internal Coping Skills

    Assess suicide-related internal coping skills (7 items on 5-point scales; scores range from 0 to 28 with higher scores indicating better internal coping). Assessed in patients only.

    Time frame: Baseline; 3 months; 6 months

  8. Suicide-Related Coping Scale (SRCS) - External Coping Skills

    Assess suicide-related internal coping skills (7 items on 5-point scales; scores range from 0 to 28 with higher scores indicating better external coping). Assessed in patients only.

    Time frame: Baseline; 3 months; 6 months

  9. Mean Generalized Anxiety Disorder (GAD-7) score

    Anxiety measured with GAD-7, a 7 item self report instrument that measures anxiety Items are scored on a 4-point scale, ranging from "not at all (0)" to "nearly everyday (3)". Item scores are summed with a total score ranging from 0 to 21: 0-4 Minimal anxiety; 5-9 Mild anxiety; 10-14 Moderate anxiety; 15-21 Severe anxiety. Assessed in patients only.

    Time frame: Baseline; 3 months; 6 months

  10. Mean Social Connectedness Scale score

    The Social Connectedness Scale consists of 8 items that assess perceived sense of closeness, belonging, and connection with others. The scale consists of multiple items that ask respondents to rate their agreement on a scale of 1 to 5, with 1 indicating strong disagreement and 5 indicating strong agreement. Higher scores indicate higher social connection. Assessed in patients only.

    Time frame: Baseline; 3 months; 6 months

  11. Client Service Receipt Inventory to assess health service uptake

    Percent services utilized will be assessed using the Client Services Receipt Inventory which measures use of health and social care services ranging from community delivered care from community health workers, to primary care services, to specialist services, and traditional health services. Assessed in patients only.

    Time frame: Baseline; 3 months; 6 months

07

Study locations

1 of 1 sites recruiting
  • Primary care facilities
    Dolakhā, Nepal
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Only de-identified data will be shared through NIH designated data repositories consistent with data sharing under the NIH GDS policy. Clinical data of those research participants who will provide consent for sharing their data will be be included.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07362056
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Nov 15, 2025
Primary completion
Jul 15, 2027 (estimated)
Completion
Aug 15, 2027 (estimated)
Last update
Jan 23, 2026

Study contacts

Ashley K Hagaman, PhD, MPH
Contact
ashley.hagaman@yale.edu
2487908954
Ashley K Hagaman, PhD, MPH
principal investigator · Yale School of Public Health

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion